BioInc@NYMC hosted a grand opening ribbon cutting event on December 6 to welcome its anchor client, Philips Healthcare Research. Thirteen employees from the Philips’Intellispace Genomics R&D team will occupy 1,300-square-feet in the biotechnology incubator to work on oncology genomics and collaborative computational genomics of large data sets. Leadership and staff from BioInc, NYMC, Philips and local officials were on hand to commemorate the momentous occasion. From left: Autri Dutta, head of operations and strategic marketing, genomics, Philips; Randi D. Schwartz, M.B.A., director, BioInc@NYMC and associate dean for academic administration, School of Medicine; William M. Mooney, III, Esq., director of the Office of Economic Development, Westchester County; Hans-Aloys Wischmann, Ph.D., head of Research North America, Philips; Robert W. Amler, M.D., M.B.A., dean of the School of Health Sciences and Practice and vice president for government affairs; Sherlita Amler, M.D., Westchester County Commissioner of Health, clinical associate professor of pediatrics, School of Medicine, and distinguished lecturer in School of Health Sciences and Practice; D. Douglas Miller, M.D., C.M., M.B.A., dean of the School of Medicine, vice-provost for biomedical affairs at Touro College and University System and chief scientific officer of BioInc@NYMC; Laurence Gottlieb, president and chief executive officer of the Hudson Valley Economic Development Corporation; Robert P. Astorino, Westchester County Executive; Sri Venkatarama, senior director and clinical research board director, Philips; Terrence P. Murphy, New York State Senator; John T. Fallon III, M.D., Ph.D., professor and chairman of the Department of Pathology; and Nevenka Dimitrova, Ph.D., chief technology officer, Philips. Read the press release here. View the ribbon cutting photo gallery here.
This new customized space in BioInc will allow Philips to collaborate closely with researchers at NYMC and be in close proximity to NYMC’s affiliate, Westchester Medical Center, where they offer Philips’ genomics technology for personalized cancer treatment.
“This is important work that is highly consistent with the U.S. government’s National Institutes of Health Precision Medicine Initiative, the Cancer Moonshot and the Human Microbiome Project,” said D. Douglas Miller, M.D., C.M., M.B.A., dean of the School of Medicine, vice-provost for biomedical affairs at Touro College and University System and chief scientific officer of BioInc@NYMC. “We are very pleased to see this important work continue in this new state-of-the-art research venue. This relationship serves the scientific mission that drives the Philips and NYMC innovation platforms forward, and provides great economic impact to this region and to our state.”
Hans-Aloys Wischmann, Ph.D., head of Philips Research Americas, expressed his appreciation for the partnership, collaboration, hospitality, environment and infrastructure that BioInc@NYMC represents and their shared vision to potentially impact three billion lives. “We would like to say thank you today for … never letting go of that vision that this is something that will be beneficial to patients in the future because I think that’s one of the things that unites us. You, as a medical college with a health care system, and us, as a health care solutions provider that we aspire to be…”
New York State Senator Terrence P. Murphy called the Philips/BioInc relationship the perfect solution for the three P's — public-private-partnership.
“…This is becoming the hottest spot in America for biotech and life sciences,” Westchester County Executive Robert P. Astorino said proudly. “The future of medicine is being developed right here.”
Randi D. Schwartz, M.B.A., director, BioInc@NYMC and associate dean for academic administration, School of Medicine, closed the program saying, “This new relationship between Philips and BioInc is an excellent example of what can happen when the academic and business communities join together. This relationship is a win-win-win for everyone. Philips is winner, BioInc is a winner, and most importantly the entire Westchester community is a winner.”